What is the prevalence of Osteopetrosis?

Osteopetrosis is a rare genetic condition characterized by impaired bone resorption, with prevalence estimates varying significantly based on the specific subtype. While autosomal recessive Osteopetrosis (ARO) is considered ultra-rare with an incidence of approximately 1 in 250,000 births, the milder autosomal dominant form (ADO) is more common, estimated at 1 in 20,000 to 1 in 250,000 individuals globally. These numbers are likely underestimates due to frequent misdiagnosis or asymptomatic cases.

Is Osteopetrosis considered rare or ultra-rare?

The classification of Osteopetrosis depends on the clinical form. Severe autosomal recessive Osteopetrosis is classified as ultra-rare, often presenting in infancy with life-threatening complications. Conversely, autosomal dominant Osteopetrosis (also known as Albers-Schönberg disease) is considered rare but has a higher prevalence, often manifesting later in life. Because symptoms vary from incidental findings on X-rays to severe bone marrow failure, many individuals may go undiagnosed for years, making precise epidemiological tracking difficult.

How does Osteopetrosis affect different populations?

Osteopetrosis does not show a strong gender bias, affecting males and females with equal frequency. However, there are notable geographic and ethnic variations, particularly for the recessive forms, which are more frequently reported in regions with higher rates of consanguinity. Age of onset is highly variable:

• Infantile/Malignant Osteopetrosis: Typically presents in the first few months of life.


• Intermediate Osteopetrosis: Often diagnosed in childhood or adolescence.


• Autosomal Dominant Osteopetrosis: Frequently diagnosed in adulthood, sometimes incidentally.

Why is accurate data for Osteopetrosis difficult to obtain?

Accurate prevalence data for Osteopetrosis remains a challenge due to the broad spectrum of clinical severity. Mild cases of Osteopetrosis are often asymptomatic and never identified, while severe cases may be misattributed to other hematological or skeletal disorders. At DiseaseMaps.org, we have 43 community members living with Osteopetrosis who share their lived experiences, providing a crucial, real-world perspective that complements clinical data by highlighting the diagnostic journey of patients globally.

Next steps

• Consult with a clinical geneticist to confirm the specific subtype of Osteopetrosis through molecular testing.


• Connect with the 43 members on DiseaseMaps.org to share insights on symptom management and finding specialized care.


• Request a referral to a metabolic bone center or an orthopedic specialist experienced in rare skeletal dysplasias.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always seek the counsel of your healthcare provider for diagnosis and treatment.

References

• Orphanet (ORPHA:654): Osteopetrosis.


• NIH Genetic and Rare Diseases Information Center (GARD): Osteopetrosis.


• OMIM (Online Mendelian Inheritance in Man): Osteopetrosis, Autosomal Dominant and Recessive entries.


• The Osteopetrosis Support Trust: Patient resources and clinical research updates.